Enbrel® is approved across 7 indications, including paediatric indications¹

• Enbrel in combination with methotrexate is indicated for the treatment of moderate-to-severe active RA in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate¹
• Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate¹

• Enbrel is also indicated in the treatment of severe, active and progressive RA in adults not previously treated with methotrexate¹​​​​​​​

Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function¹

Please refer to the ENBREL Summary of Product Characteristics for full prescribing information